Paper Details

  1. Home
  2. Paper Details

Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial.

Author: BourgeRobert C, CerkvenikJeffrey, ChakinalaMurali M, FeldmanJeremy P, FrantzRobert P, Gomberg-MaitlandMardi, MorrisMarty, PetersonLeigh, RubinLewis J, ShapiroShelley M, TarverJames H, ThalinMelissa, TorresFernando, WaxmanAaron B, ZwickeDianne L

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

A fully implantable intravascular delivery system for treprostinil infusion shows promise for treating severe pulmonary arterial hypertension (PAH). This novel system could offer a less invasive and more convenient alternative to current pump-delivered continuous therapy.
Paper Details　
Original Abstract of the Article :
The use of systemic prostanoids in severe pulmonary arterial hypertension (PAH) is often limited by patient/physician dissatisfaction with the delivery methods. Complications associated with external pump-delivered continuous therapy include IV catheter-related bloodstream infections and subcutaneou...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.chest.2015.11.005

データ提供：米国国立医学図書館（NLM）

Treprostinil for PAH: A New Oasis in the Desert of Treatment Options

Pulmonary arterial hypertension (PAH) is a serious and debilitating condition, like a treacherous sandstorm in the lungs. This study, like a group of resourceful explorers, investigates the use of a fully implantable intravascular delivery system for treprostinil, a potent prostanoid, to treat PAH. The authors explore the challenges associated with traditional delivery methods, highlighting the need for a more convenient and less invasive approach. This innovative delivery system, like a well-stocked caravan, aims to provide continuous infusion of treprostinil without the drawbacks of external pump-delivered therapy, potentially offering a more manageable and effective treatment for patients with PAH.

Treprostinil Delivery: A New Path Through the Desert of PAH

This research highlights the potential for a fully implantable delivery system to revolutionize the treatment of PAH. The innovative approach offers a more convenient and less invasive option for patients, potentially improving their quality of life and treatment outcomes.

Treprostinil Delivery: A Glimmer of Hope for PAH Patients

PAH can be a challenging condition, but this research offers a glimmer of hope for patients seeking a more effective and convenient treatment. The development of a fully implantable delivery system could significantly improve the management of this debilitating disease.

Dr.Camel's Conclusion

The fully implantable intravascular delivery system for treprostinil is like a hidden oasis in the desert of PAH treatment. This innovative approach holds promise for improving the lives of patients with this serious condition. It's a reminder that even in the most challenging medical landscapes, there are always new discoveries waiting to be made.

Date :
  1. Date Completed 2017-05-02
  2. Date Revised 2022-03-18
Further Info :

Pubmed ID

27396777

DOI: Digital Object Identifier

10.1016/j.chest.2015.11.005

Related Literature

Article Analysis
・Side Effects of epoprostenol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.